How dinosaur fossils became collectables for the mega-rich
Dinosaur fossils are prized like blue-chip artworks and are even accelerating past the prices of many Old Masters paintings, says Chris Carter
Last week, the fossilised bones of a stegosaurus and an adult and juvenile allosaurus were seized under the Proceeds of Crime Act, alongside nine luxury flats in London and a collection of Chinese artworks. The forfeiture relates to an ongoing investigation into alleged money-laundering by Su Binghai, a Singapore-based businessman. That dinosaur fossils are listed among the seized assets, along with property and art, shouldn’t surprise us, says David Brown in The Times. “Dinosaur skeletons and bones have become the status item of choice for the mega-rich in recent times, with ancient fossilised remains accelerating past the prices of many Old Masters paintings.” The fossils had sold for a combined £12.4 million, including the buyer’s premium, in London last December at auction with Christie’s.
There’s “something powerful about the visual dialogue between an awe-inspiring 66-million-year-old lot and seminal works from the modern and contemporary eras”, says Miety Heiden, head of private sales at Phillips. The auction house is offering a complete skeleton of a juvenile Triceratops as the highlight of its “Out of This World” sale in New York on 19 November. “Cera”, as the triceratops has been named, is expected to fetch between $2.5 /million and $3.5 million. “Today’s collectors want to spice things up,” Christian D. Link, a Swiss expert who has partnered with Phillips, tells The Times. “They’re like the collectors of the Renaissance who liked to surround themselves with amazing things in their ‘chambers of wonders’.” That, says Link, explains the rise in prices. In 2020, a 67-million-year-old T. rex, called “Stan”, sold for $31.8 million, a record-high auction price until July 2024, when billionaire investor Ken Griffin paid $44.6 million for a 150-million-year-old stegosaurus, called “Apex”.
The problem with buying dinosaur fossils
Apex is now on display at the American Museum of Natural History. But loans don’t always solve the problem of scientific access. “Access to dinosaurs on loan… could be taken away at any point, meaning it would be impossible to verify any conclusions made using them,” Professor Richard Butler tells James Ashworth on the Natural History Museum blog. So, some palaeontologists prefer to simply ignore them.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The arguments for and against commercial sales of fossils are many – and not all palaeontologists call for a blanket ban. But private ownership can also make it hard for scientists to know how many of a particular kind of fossil exists – say, that of a specific creature, and that can make tracking “variation” tricky. “Spike”, a 68-million-year-old caenagnathid dinosaur skeleton, for instance, has a mark that suggests it was feathered. It is for sale with Christie’s in London on 11 December, when it is expected to fetch between £3 million and £5 million.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Three Indian stocks to buy for long-term profit growthOpinion Rita Tahilramani and James Thom, co-managers at the Aberdeen New India Investment Trust, highlight three Indian stocks to buy now
-
Hiring new staff for your business? Help is availableHiring more employees is a costly business, but help is available from the government, says David Prosser
-
Polar Capital: a cheap, leveraged play on technologyPolar Capital has carved out a niche in fund management and is reaping the benefits
-
Vaccines inject billions into Big Pharma – how to profit from the sectorThe vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Here's what it means for investors
-
'Investors should keep putting their trust in investment trusts'Interview Peter Walls, manager of the Unicorn Mastertrust fund, analyses investment trusts in a conversation with Andrew Van Sickle
-
Monks Investment Trust is worthy of the spotlightMonks Investment Trust, a global growth trust, sits in the shadow of its stablemate, Scottish Mortgage. But its record warrants attention, says Max King
-
New year, same market forecastsForecasts from banks and brokers are as bullish as ever this year, but there is less conviction about the US, says Cris Sholto Heaton
-
'Expect more policy U-turns from Keir Starmer'Opinion Keir Starmer’s government quickly changes its mind as soon as it runs into any opposition. It isn't hard to work out where the next U-turns will come from
-
Why does Donald Trump want Venezuela's oil?The US has seized control of Venezuelan oil. Why and to what end?
-
Britain heads for disaster – what can be done to fix our economy?Opinion The answers to Britain's woes are simple, but no one’s listening, says Max King
